Dr. Ashley F. Lanzel

Holly Meany, MD, is a pediatric oncologist and director of the Solid Tumor Program at Children’s National Hospital. She also serves as an associate professor of pediatrics at George Washington University. Dr. Meany is dedicated to finding better treatments for children with cancer through research and clinical care. Her work focuses on developing new therapies for pediatric solid tumors. She designs and leads early-phase clinical trials to test promising treatments and understand how they work in children. Dr. Meany has played a key role in several national studies, including large trials for neuroblastoma, a type of childhood cancer. She recently led an international study for children with newly diagnosed non-high-risk neuroblastoma and is currently helping to develop the next high-risk neuroblastoma trial, both through the Children’s Oncology Group. Dr. Meany is also exploring innovative approaches like immunotherapy—using the body’s own immune system to fight cancer. She has led international studies using specialized T cells to treat patients with relapsed solid tumors and is now working on combining these novel T cells with CAR T-cell therapy for children with relapsed cancers. In addition to her research, Dr. Meany is passionate about training the next generation of pediatric cancer specialists. As director of the Pediatric Hematology-Oncology Fellowship Program at Children’s National, she mentors and supports future leaders in the field. Dr. Meany is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Neuroblastoma, Hereditary Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Osteosarcoma, and Mastoidectomy. Dr. Meany is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2006 and Pediatrics: American Board Of Pediatrics, 2003.

Urania Dagalakis, MD, MHSc, specializes in pediatric oncology and hematology. She completed her clinical training at Johns Hopkins University and conducted her research work within the National Cancer Institute of the National Institutes of Health. Due to her research background she specializes in caring for children with rare tumors and hereditary cancer syndromes. Dr. Dagalakis is the director of the Cancer Genetics Clinic at Children’s National Hospital. She is also an assistant professor of pediatrics at The George Washington University School of Medicine and Health Sciences and a physician in the Center for Cancer and Blood Disorders. She is committed to empowering families with knowledge, supporting survivorship and leading innovations in personalized cancer care. Her work bridges compassionate patient care with clinical research focused on improving outcomes for children with genetic cancer predispositions. Dr. Dagalakis is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Hemoglobin SC Disease and Immune Thrombocytopenic Purpura (ITP). Dr. Dagalakis is board certified in Pediatrics: American Board Of Pediatrics, 2023.

Lea Mayer is a Pediatric Hematologist Oncology provider practicing medicine in Washington, Washington, D.c.. Dr. Mayer is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Hereditary Neuroblastoma, Neuroblastoma, Ewing Sarcoma, and Osteosarcoma. Dr. Mayer is board certified in Oncology Nursing Certification Corporation, 2015 and Primary Care Certified Pediatric Nurse Practitioner (CPNP-PC): Pediatric Nursing Certification Board, 2010.

Luca Szalontay is a Pediatric Hematologist Oncology provider practicing medicine in Washington, Washington, D.c.. Dr. Szalontay is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Glioma, Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, and Brain Stem Cancer. Dr. Szalontay is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2021 and Pediatrics: American Board Of Pediatrics, 2015. Dr. Szalontay is currently accepting new patients.

Hyojeong Han is a Pediatric Hematologist Oncology specialist and a Transfusion Medicine provider practicing medicine in Washington, Washington, D.c.. Dr. Han is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Anemia, and Hemolytic Anemia. Dr. Han is board certified in American Board Of Pathology, 2021, American Board Of Pediatrics, 2021, and American Board Of Pediatrics, 2016. Dr. Han is currently accepting new patients.

AeRang Kim, MD, PhD, is a member of the solid tumor faculty at Children’s National Hospital and an Associate Professor of Pediatrics. Dr. Kim's specializes in sarcomas and developmental therapeutics. Her research focuses on development of novel therapeutics for pediatric cancer including pre-clinical testing of novel agents, pharmacokinetic analysis, developing innovative methods for toxicity monitoring and clinical trial design. She serves as the principal investigator of multiple early phase trials in pediatric oncology, sarcomas and NF1 associated tumors. Her clinical expertise encompasses Osteosarcoma, Rhabdomyosarcoma, Rhabdoid Tumor, and Malignant Peripheral Nerve Sheath Tumor. Dr. Kim is board certified in Pediatrics: American Board Of Pediatrics, 2004 and Pediatric Hematology-Oncology: American Board Of Pediatrics, 2009.